Cerebrolysin for acute ischaemic stroke.
CONCLUSIONS: Moderate-quality evidence indicates that Cerebrolysin probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke, or on the total number of people with serious adverse events. Moderate-quality evidence also indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use.
PMID: 32662068 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Ziganshina LE, Abakumova T, Hoyle CH Tags: Cochrane Database Syst Rev Source Type: research
More News: Brain | Cardiology | China Health | Conferences | Databases & Libraries | General Medicine | Grants | Heart | Heart Failure | Ischemic Stroke | Neurology | Neuroscience | Pneumonia | Pulmonary Thromboembolism | Russia Health | Science | Statistics | Stroke | Study